Oncology nurses at local and specialized centers can work together to create a pathway for patients throughout CAR T-cell therapy treatment. Over the 30 years Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has worked at Cleveland Clinic as a PhD researcher and adult patient nurse practitioner, she’s seen how treatments for patients with multiple myeloma have evolved. When Faiman began working at Cleveland Clinic in 1994, there were few good treatments available for multiple myeloma, a rare blood cancer that develops in plasma cells in the bone marrow. It wasn’t unusual for patients to live only 2 to 3 years after receiving a diagnosis. Today, the outlook for patients with multiple myeloma has greatly improved, with treatments going beyond surgery, chemotherapy, and radiation to include new immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy.